Live Breaking News & Updates on Daniel Pearlstein

Stay updated with breaking news from Daniel pearlstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

POINT Biopharma Prices Public Offering of Common Stock

INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the. ....

New York , United States , Daniel Pearlstein , Piper Sandler , Equity Syndicate Department , Guggenheim Securities , Oppenheimer Co , Biopharma Global Inc , Exchange Commission , Syndicate Prospectus Department , Prospectus Department , Piper Sandler Co , Common Stock , Private Securities Litigation Reform Act , Relations Contact , Nasdaq Pnt , Point Biopharma , Actinium 225 , Clinical Trials , Lutetium 177 , Nasdaq Pnt , Oncology Clinical Trials ,

POINT Biopharma Provides Updated Efficacy and Safety Data

Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A. ....

United Kingdom , United States , Kim Chi , Daniel Pearlstein , Neil Fleshner , Aaronr Hansen , Scott Tagawa , Oliver Sartor , University Of Toronto , Professor Of Medicine At Meyer Cancer Center , University Of Queensland , Biopharma Global Inc , Chief Medical Officer , Deputy Director , Cancer Services , Metro South Health , Medical Oncologist , Princess Alexandra Hospital , Associate Professor , North America , Metastatic Castration Resistant Prostate Cancer , Initial Results , Weill Cornell Medicine , Meyer Cancer Center , Englj Med , Private Securities Litigation Reform Act ,

POINT Biopharma Announces Poster Presentation at ESMO

Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. . ....

United States , France General , United Kingdom , Daniel Pearlstein , Aaronr Hansen , University Of Toronto , Biopharma Global Inc , Specific Membrane Antigen , Metastatic Castration Resistant Prostate Cancer , Initial Results , Princess Alexandra Hospital , Associate Professor , North America , Private Securities Litigation Reform Act , Relations Contact , Nasdaq Pnt , Point Biopharma , Actinium 225 , Lutetium 177 , Nasdaq Pnt , Oncology Clinical Trials , Clinical Trials ,

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , France General , United Kingdom , Sherin Al Safadi , Kim Chi , Daniel Pearlstein , Oliver Sartor , University Of Tulane School Medicine , British Columbia Cancer Agency , Tulane Cancer Center , Vp Medical Affairs , Biopharma Global Inc , Specific Membrane Antigen , Metastatic Castration Resistant Prostate Cancer , Initial Results , Medical Director , Tulane School , Vice President , Chief Medical Officer , British Columbia Cancer , North America , Private Securities Litigation Reform Act , Relations Contact , Globe Newswire ,

POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , United Kingdom , Joe Mccann , Daniel Pearlstein , Novartis Institutes For Biomedical Research , Rutgers Business School , University Of Guelph , Society For Nuclear Medicine , Biopharma Global Inc , Development Expenses , American Association For Cancer Research , Wilfrid Laurier University , European Union , Health Canada , North America , American Association , Cancer Research , Nuclear Medicine , Molecular Imaging , Chris Horvath , Executive Vice President , Novartis Institutes , Advanced Accelerator Applications , Analytical Science , Rutgers Business , Six Months Ended ,